154 related articles for article (PubMed ID: 8129642)
1. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
Polman CH; Bertelsmann FW; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Mar; 51(3):292-6. PubMed ID: 8129642
[TBL] [Abstract][Full Text] [Related]
2. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Polman CH; Bertelsmann FW; de Waal R; van Diemen HA; Uitdehaag BM; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
[TBL] [Abstract][Full Text] [Related]
3. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
[TBL] [Abstract][Full Text] [Related]
4. 4-Aminopyridine in multiple sclerosis: prolonged administration.
Stefoski D; Davis FA; Fitzsimmons WE; Luskin SS; Rush J; Parkhurst GW
Neurology; 1991 Sep; 41(9):1344-8. PubMed ID: 1891078
[TBL] [Abstract][Full Text] [Related]
5. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
Bever CT; Young D; Anderson PA; Krumholz A; Conway K; Leslie J; Eddington N; Plaisance KI; Panitch HS; Dhib-Jalbut S
Neurology; 1994 Jun; 44(6):1054-9. PubMed ID: 8208399
[TBL] [Abstract][Full Text] [Related]
6. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
Davis FA; Stefoski D; Rush J
Ann Neurol; 1990 Feb; 27(2):186-92. PubMed ID: 2317014
[TBL] [Abstract][Full Text] [Related]
7. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
[TBL] [Abstract][Full Text] [Related]
8. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
9. 10 questions about 4-aminopyridine and the treatment of multiple sclerosis.
Bever CT
Neurologist; 2009 May; 15(3):161-2. PubMed ID: 19430274
[No Abstract] [Full Text] [Related]
10. Assessment of the efficacy and safety of fampridine.
Mejuto B; Castellano P; Castro C; López LM
Farm Hosp; 2017 Mar; 41(2):283-291. PubMed ID: 28236802
[TBL] [Abstract][Full Text] [Related]
11. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
Van Diemen HA; Polman CH; Koetsier JC; Van Loenen AC; Nauta JJ; Bertelsmann FW
Clin Neuropharmacol; 1993 Jun; 16(3):195-204. PubMed ID: 8504436
[TBL] [Abstract][Full Text] [Related]
12. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Arreola-Mora C; Silva-Pereyra J; Fernández T; Paredes-Cruz M; Bertado-Cortés B; Grijalva I
Mult Scler Relat Disord; 2019 Feb; 28():117-124. PubMed ID: 30593980
[TBL] [Abstract][Full Text] [Related]
13. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Smits RC; Emmen HH; Bertelsmann FW; Kulig BM; van Loenen AC; Polman CH
Neurology; 1994 Sep; 44(9):1701-5. PubMed ID: 7936300
[TBL] [Abstract][Full Text] [Related]
14. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy?
De Cauwer H; De Wolf P; Couvreur F; Mortelmans L
Acta Neurol Belg; 2009 Mar; 109(1):40-1. PubMed ID: 19402572
[TBL] [Abstract][Full Text] [Related]
15. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
Mathiesen HK; Sorensen PS
Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
[TBL] [Abstract][Full Text] [Related]
16. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
17. Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ
Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of dalfampridine in patients with multiple sclerosis.
Ruck T; Bittner S; Simon OJ; Göbel K; Wiendl H; Schilling M; Meuth SG
J Neurol Sci; 2014 Feb; 337(1-2):18-24. PubMed ID: 24290498
[TBL] [Abstract][Full Text] [Related]
19. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
Bever CT; Leslie J; Camenga DL; Panitch HS; Johnson KP
Ann Neurol; 1990 Apr; 27(4):421-7. PubMed ID: 2353797
[TBL] [Abstract][Full Text] [Related]
20. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
